Clik here to view.
Monday Deal Review: November 19, 2012
Welcome to your Monday Biotech Deal Review for November 19, 2012. This past week saw the FTC give Valeant formal approval to acquire Medicis. A busy week on the investment front saw Kane Biotech,...
View ArticleClik here to view.
Monday Deal Review: November 26, 2012
Welcome to your Monday Biotech Deal Review for November 26, 2012. This past week saw Valeant continue their aggressive stock repurchase program. Valeant plans to repurchase up to $1.5 billion worth of...
View ArticleClik here to view.
Capital Markets – The Biotech Analyst: Part 21 of Valuation and Other Biotech...
[Ed. This is the twenty-first part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this...
View ArticleClik here to view.
Some Questions When Considering Investing in Canadian Healthcare Stocks: Part...
[Ed. This is the twenty-second part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in...
View ArticleClik here to view.
Friday Science Review: November 30, 2012
Autism spectrum disorder (ASD) encompasses a range of developmental disorders that effect multiple basic functions including language and socialization. Specific causes of ASD have not been determined,...
View ArticleClik here to view.
Monday Deal Review: December 3, 2012
Welcome to your Monday Biotech Deal Review for December 3, 2012. An unusually high number of private placements characterized the past week’s Canadian biotech activity, with Biosign Technologies...
View ArticleClik here to view.
Investing in Junior Mining –Consider Biotech Stocks Also: Part 23 of...
[Ed. This is the twenty-third part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this...
View ArticleClik here to view.
Monday Deal Review: December 10, 2012
Welcome to your Monday Biotech Deal Review for December 10, 2012. This week saw significant activity in the commercial and licensing agreements arena, as well as a couple M&Eh transactions. Of...
View ArticleClik here to view.
Monday Deal Review: December 17, 2012
Welcome to your Monday Biotech Deal Review for December 17, 2012. This week saw the completion of a number of previously announced acquisitions, as well as the announcement of new ones. The latter...
View ArticleClik here to view.
Monday Deal Review: December 24, 2012
Welcome to your Monday Biotech Deal Review for December 24, 2012. While the past week was relatively slow as everyone prepared for holiday breaks, there was nonetheless a series of option grants,...
View ArticleClik here to view.
Monday Deal Review: January 7, 2013
Happy New Year and welcome to your Monday Biotech Deal Review for January 7, 2013! While biotech gets back to business for 2013 after the holidays, the last 2 weeks have not seen a flurry of activity....
View ArticleClik here to view.
Friday Science Review: January 8, 2013
Ubiquitin-specific proteases (USPs) are implicated in many diseases and yet only a few weak inhibitors of their function have been available. A report in Science from a collaboration led by the Siddhu...
View ArticleClik here to view.
Monday Deal Review: January 14, 2013
Welcome to your Monday Biotech Deal Review for January 14, 2013! This week’s big news is that Cytochroma, a privately held company, will be acquired by OPKO Health. Also on the M&A side,...
View ArticleClik here to view.
Monday Deal Review: January 21, 2013
Welcome to your Monday Biotech Deal Review for January 21, 2013! Medicago made news last week with a $15 million loan agreement with an unnamed pharmaceutical company. The funds are being used for...
View ArticleClik here to view.
Monday Deal Review: January 28, 2013
Welcome to your Monday Biotech Deal Review for January 28, 2013! The past week was relatively quiet, but highlights include Sernova’s $2 million private placement and Helix’s closing of their $8.5...
View ArticleClik here to view.
Monday Deal Review: February 4, 2013
Welcome to your Monday Biotech Deal Review for February 4, 2013! This week saw significant activity in the sector generally On the M&A side, Valeant continued their ongoing acquisition strategy,...
View ArticleClik here to view.
Monday Deal Review: February 11, 2013
Welcome to your Monday Biotech Deal Review for February 11, 2013! This week saw YM Biosciences obtain the required court approval necessary before their plan of arrangement acquisition by Gilead could...
View ArticleClik here to view.
Friday Science Review: February 15, 2013
The Dick lab at the Campbell Family Cancer Research Institute has a prestigious history of unraveling the complexities of cancer and their recent publication in Science adds yet more detail. Analysis...
View ArticleClik here to view.
Monday Deal Review: February 18, 2013
Welcome to your Monday Biotech Deal Review for February 18, 2013! This week saw Gilead finally close its acquisition of YM Biosciences, with YM’s shares now de-listed from trading on the NYSE Amex and...
View ArticleClik here to view.
2012 Canadian Healthcare Share Price Performance – volatile with opportunities
A group of 96 Canadian healthcare companies, which was assessed for 2012 share price performance is extremely diverse, with market caps ranging from about $1 million to $10 billion, but most less than...
View Article
